查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2046640

大腸癌篩檢和診斷市場 - 全球產業規模、佔有率、趨勢、機會、預測：篩檢、診斷、最終用戶、地區和競爭格局，2021-2031年

Colorectal Cancer Screening and Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Screening, By Diagnostics, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球大腸癌篩檢和診斷市場預計將從 2025 年的 187.8 億美元成長到 2031 年的 248.5 億美元，複合年成長率為 4.78%。

這個不斷擴大的市場涵蓋了各種醫療設備、先進的糞便檢驗方法以及專為早期檢測結直腸和直腸組織中的癌前病變和惡性腫瘤而設計的先進成像系統。推動該市場成長的關鍵因素包括全球大腸直腸癌發病率的上升以及老齡化社會對更頻繁健康監測日益成長的需求。此外，全國性篩檢計畫的實施以及建議降低篩檢年齡的修訂指南正在積極擴大目標患者群體。例如，美國癌症協會估計，到2025年，光是美國就將新增154,270例大腸癌病例，凸顯了有效診斷介入措施的重要性。

市場概覽
預測期 2027-2031
市場規模：2025年 187.8億美元
市場規模：2031年 248.5億美元
複合年成長率：2026-2031年 4.78%
成長最快的細分市場 生物標記檢測
最大的市場 北美洲

儘管市場成長勢頭良好，但主要源自於患者對推薦篩檢方案依從性低的重大挑戰，阻礙了市場充分發揮其潛力。傳統的檢查方法，例如大腸鏡檢查，屬於侵入性檢查，需要患者感到不適並進行細緻的準備，這往往導致人們對接受這些重要的檢查猶豫不決。除了人們普遍對這些侵入性檢查方法的抵觸情緒外，許多發展中地區普遍存在的醫療報銷體係不完善也是篩檢技術廣泛應用的主要障礙，從而阻礙了市場的整體發展。

市場促進因素

推動市場發展的主要因素是全球大腸直腸癌發生率的不斷上升。診斷方案正在不斷擴展，以應對尤其是在年輕人群體中日益成長的發病率。世界各地的醫療衛生系統都在加強診斷工作，以直接應對日益嚴重的疾病負擔，這需要廣泛採用成熟和創新的篩檢工具。這種疾病發生率的激增不僅限於老年人群體，在年輕人群體中也同樣存在，從而在國際醫療衛生網路中持續催生了對診斷耗材和先進篩檢基礎設施的需求。世界衛生組織（世衛組織）在2024年2月報告稱，結直腸癌將成為全球第二大癌症死亡原因，2022年新增病例約190萬例，凸顯了對可擴展診斷解決方案的迫切需求。

同時，非侵入性篩檢方法的廣泛應用正在有效克服傳統上阻礙患者參與檢測的障礙，從根本上改變了我們的診斷方式。市場正迅速從傳統的侵入性大腸鏡檢查轉向更便捷的替代方案，例如糞便DNA檢測和液態生物檢體，這顯著提高了患者的參與度。新一代篩檢產品的商業性成功清晰地證明了這一轉變，這些產品能夠無縫融入常規醫療保健。例如，Guardant Health在2024年7月發布的關於其Shield產品獲得FDA核准的新聞稿中強調，該公司在真實臨床環境中的血液檢測完成率超過90%，滿足了人們對更便捷檢測方式的迫切需求。此外，像Exact Sciences這樣老字型大小企業也表現出色，該公司在2024年11月發布的第三季財報中公佈了5.45億美元的篩檢收入，這凸顯了非侵入性診斷解決方案的強勁普及和蓬勃發展。

市場挑戰

患者對強制性篩檢的低依從性是全球大腸直腸癌篩檢和診斷市場擴張的主要障礙。這種抵抗情緒主要源自於標準診斷程序的侵入性，尤其是大腸鏡檢查。這些檢查通常需要嚴格的準備程序，並會造成身體不適。因此，相當一部分目標族群會避免或延遲必要的檢查，直接導致檢查數量減少，而檢查數量的減少通常會推動對影像系統和診斷耗材的需求。

目標患者群體與實際篩檢率之間的差距是市場成長的一大瓶頸。即使更新指南擴大了目標族群，人們對侵入性檢測的抵觸情緒仍然顯著限制了醫療設備和檢測套組製造商的潛在市場規模。 2025年全國大腸直腸癌圓桌會議的數據顯示，超過三分之一的45歲以上成年人未依建議接受篩檢。這項統計數據清楚地表明，市場發展軌跡並非僅取決於疾病盛行率或技術可近性，而是受到患者難以廣泛遵守篩檢方案這一持續難題的嚴重限制。

市場趨勢

將人工智慧 (AI) 應用於內視鏡檢查，從根本上提高了傳統大腸鏡檢查的診斷準確性，有效地減少了息肉檢出過程中的人為誤差。這一新趨勢著重於電腦輔助檢測 (CADe) 系統的應用，該系統透過即時分析影像數據並突出顯示潛在病變，從而彌補了內視鏡醫師能力上的差異。與微創檢查的趨勢相反，這項技術透過提高腺瘤檢出率，增強了侵入性檢查的臨床價值。 Medscape 於 2024 年 11 月引用的一篇題為「AI 輔助大腸鏡檢查將腺瘤檢出率提高 20%：Meta分析」的系統評價顯示，AI 輔助大腸鏡檢查將腺瘤檢出率提高了 20%，這表明該技術在最大限度地減少漏診和改善患者預後方面發揮著關鍵作用。

同時，多體學和新型生物標記發現技術的進步，正透過高靈敏度的新一代檢測方法，針對大規模篩檢的人群，拓展市場。這一趨勢的驅動力在於複雜RNA和DNA特徵的識別，這些特徵比傳統的糞便檢驗具有更高的準確性，促使製造商開發獨特的早期檢測解決方案。這項創新背後的商業性驅動力在於目前未遵循現有篩檢方案的人所蘊藏的巨大未開發潛力。根據Mainz Biomed公司2024年12月發布的新聞稿《Mainz Biomed與Quest Diagnostics達成協議》，美國居住者中持續存在的篩檢缺口代表著超過40億美元的市場機遇，這推動了對新型生物標記檢驗的大量投資，以期抓住這一目標群體。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章 全球大腸癌篩檢與診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 篩檢方法（糞便檢驗、大腸鏡檢查和乙狀結腸鏡檢查等）
    • 依類型診斷（生物標記檢測、大腸鏡檢查）
    • 依最終使用者（醫院/診所、臨床實驗室、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美大腸癌篩檢與診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲大腸癌篩檢與診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區大腸直腸癌篩檢與診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲大腸直腸癌篩檢和診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲大腸癌篩檢與診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球大腸直腸癌篩檢與診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Exact Sciences Corporation
  • Abbott Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Siemens Healthineers AG
  • Hologic, Inc.
  • Sysmex Corporation
  • Bio-Rad Laboratories, Inc.
  • Becton, Dickinson and Company

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16767

The Global Colorectal Cancer Screening and Diagnostic Market is projected to experience substantial growth, increasing from USD 18.78 billion in 2025 to USD 24.85 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 4.78%. This expansive market encompasses various medical devices, advanced stool-based assays, and sophisticated imaging systems specifically designed for the early detection of precancerous lesions and malignant growths within the colon and rectum. Key factors propelling this market expansion include the rising global incidence of colorectal cancer and an increasingly aging population that requires more frequent health monitoring. Additionally, the implementation of national screening programs and revised guidelines that recommend lowering the screening age are actively broadening the eligible patient demographic. For instance, the American Cancer Society estimated 154,270 new colorectal cancer diagnoses in the United States alone in 2025, underscoring the critical need for effective diagnostic interventions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 18.78 Billion
Market Size 2031USD 24.85 Billion
CAGR 2026-20314.78%
Fastest Growing SegmentBiomarker Test
Largest MarketNorth America

Despite this promising growth trajectory, significant challenges impede the market's full potential, primarily stemming from low patient adherence to recommended screening protocols. The inherent invasiveness of conventional procedures, such as colonoscopies, coupled with the associated discomfort and extensive preparation requirements, frequently discourages eligible individuals from undergoing vital testing. This widespread aversion to invasive methods, alongside insufficient healthcare reimbursement structures prevalent in numerous developing regions, poses a substantial barrier to the widespread adoption of screening technologies, thus hindering overall market progression.

Market Driver

A primary catalyst driving the market is the escalating global prevalence of colorectal cancer, particularly as diagnostic protocols are expanded to address the rising rates observed in younger demographics. Healthcare systems globally are intensifying their diagnostic efforts in direct response to this increasing disease burden, thereby necessitating the broad deployment of both established and innovative screening tools. This surge in disease incidence is not confined to older populations but is increasingly evident in early-onset cases, creating a sustained demand for diagnostic consumables and advanced imaging infrastructure across international healthcare networks. The World Health Organization reported in February 2024 that colorectal cancer had become the second leading cause of cancer death worldwide, with approximately 1.9 million new cases diagnosed in 2022, highlighting the urgent need for scalable diagnostic solutions.

Concurrently, the widespread adoption of non-invasive screening modalities is fundamentally transforming the diagnostic landscape by effectively overcoming historical barriers to patient compliance. The market is experiencing a rapid transition from traditional invasive colonoscopies toward more convenient alternatives such as stool-based DNA tests and liquid biopsies, which significantly enhance patient participation rates. This shift is clearly demonstrated by the commercial success of next-generation screening products that integrate seamlessly into routine medical care. For example, Guardant Health's 'Shield FDA Approval Press Release' in July 2024 highlighted a completion rate exceeding 90% for their blood-based test in real-world settings, addressing the pressing need for accessible testing options. Furthermore, the financial performance of established companies like Exact Sciences, which reported $545 million in screening revenue in their 'Third Quarter 2024 Earnings Report' in November 2024, underscores the robust adoption and vitality of non-invasive diagnostic solutions.

Market Challenge

Low patient compliance with screening mandates represents a significant obstacle to the expansion of the Global Colorectal Cancer Screening and Diagnostic Market. This resistance largely stems from the intrusive nature of standard diagnostic procedures, notably colonoscopies, which often demand rigorous preparatory steps and induce physical discomfort. Consequently, a substantial portion of the eligible population either avoids or postpones necessary testing, directly diminishing the volume of procedures that typically drive demand for imaging systems and diagnostic consumables.

This disparity between the target patient demographic and actual participation creates a critical bottleneck for market growth. Even with updated guidelines broadening the eligible population, reluctance to undergo invasive testing substantially restricts the addressable market size for manufacturers of devices and assays. Data from the National Colorectal Cancer Roundtable in 2025 indicated that over one in three adults aged 45 and older were not screened according to recommendations. This statistic emphatically illustrates that market trajectory is not solely determined by disease prevalence or technological availability, but is crucially constrained by the persistent difficulty in achieving widespread patient adherence to screening protocols.

Market Trends

The integration of Artificial Intelligence (AI) into endoscopy is fundamentally enhancing the diagnostic accuracy of conventional colonoscopies by effectively reducing human error during polyp detection. This emerging trend focuses on implementing Computer-Aided Detection (CADe) systems that analyze video feeds in real-time, highlighting potential lesions and thereby addressing the variability in endoscopist performance. In contrast to the shift towards less invasive tools, this development strengthens the clinical value of invasive procedures by ensuring greater efficacy in identifying adenomas. A systematic review cited by Medscape in November 2024, titled 'AI-Assisted Colonoscopy Increases Adenoma Detection Rate by 20%: Meta-Analysis', demonstrated that AI-assisted colonoscopy boosted the adenoma detection rate by 20%, validating the technology's crucial role in minimizing missed diagnoses and improving patient outcomes.

Simultaneously, advancements in Multi-Omics and Novel Biomarker Discovery are expanding the market by targeting the large unscreened population with highly sensitive, next-generation assays. This trend is driven by the identification of complex RNA and DNA signatures that offer superior accuracy compared to traditional fecal testing, thereby incentivizing manufacturers to develop proprietary solutions for early-stage detection. The commercial impetus for this innovation lies in the vast untapped potential of eligible individuals who currently do not comply with existing screening protocols. According to Mainz Biomed's 'Mainz Biomed Enters Agreement with Quest Diagnostics' press release in December 2024, the persistent screening gap among United States residents represents a market opportunity exceeding $4.0 billion, fueling significant investment in novel biomarker validation to capture this addressable segment.

Key Market Players

  • Exact Sciences Corporation
  • Abbott Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Siemens Healthineers AG
  • Hologic, Inc.
  • Sysmex Corporation
  • Bio-Rad Laboratories, Inc.
  • Becton, Dickinson and Company

Report Scope

In this report, the Global Colorectal Cancer Screening and Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Colorectal Cancer Screening and Diagnostic Market, By Screening

  • Stool-Based Test
  • Colonoscopy and Sigmoidoscopy
  • Others

Colorectal Cancer Screening and Diagnostic Market, By Diagnostics

  • Biomarker Test
  • Colonoscopy

Colorectal Cancer Screening and Diagnostic Market, By End User

  • Hospitals and Clinics
  • Clinical Laboratories
  • Others

Colorectal Cancer Screening and Diagnostic Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Colorectal Cancer Screening and Diagnostic Market.

Available Customizations:

Global Colorectal Cancer Screening and Diagnostic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Colorectal Cancer Screening and Diagnostic Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Screening (Stool-Based Test, Colonoscopy and Sigmoidoscopy, Others)
    • 5.2.2. By Diagnostics (Biomarker Test, Colonoscopy)
    • 5.2.3. By End User (Hospitals and Clinics, Clinical Laboratories, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Colorectal Cancer Screening and Diagnostic Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Screening
    • 6.2.2. By Diagnostics
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Colorectal Cancer Screening and Diagnostic Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Screening
        • 6.3.1.2.2. By Diagnostics
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Colorectal Cancer Screening and Diagnostic Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Screening
        • 6.3.2.2.2. By Diagnostics
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Colorectal Cancer Screening and Diagnostic Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Screening
        • 6.3.3.2.2. By Diagnostics
        • 6.3.3.2.3. By End User

7. Europe Colorectal Cancer Screening and Diagnostic Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Screening
    • 7.2.2. By Diagnostics
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Colorectal Cancer Screening and Diagnostic Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Screening
        • 7.3.1.2.2. By Diagnostics
        • 7.3.1.2.3. By End User
    • 7.3.2. France Colorectal Cancer Screening and Diagnostic Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Screening
        • 7.3.2.2.2. By Diagnostics
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Colorectal Cancer Screening and Diagnostic Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Screening
        • 7.3.3.2.2. By Diagnostics
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Colorectal Cancer Screening and Diagnostic Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Screening
        • 7.3.4.2.2. By Diagnostics
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Colorectal Cancer Screening and Diagnostic Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Screening
        • 7.3.5.2.2. By Diagnostics
        • 7.3.5.2.3. By End User

8. Asia Pacific Colorectal Cancer Screening and Diagnostic Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Screening
    • 8.2.2. By Diagnostics
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Colorectal Cancer Screening and Diagnostic Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Screening
        • 8.3.1.2.2. By Diagnostics
        • 8.3.1.2.3. By End User
    • 8.3.2. India Colorectal Cancer Screening and Diagnostic Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Screening
        • 8.3.2.2.2. By Diagnostics
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Colorectal Cancer Screening and Diagnostic Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Screening
        • 8.3.3.2.2. By Diagnostics
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Colorectal Cancer Screening and Diagnostic Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Screening
        • 8.3.4.2.2. By Diagnostics
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Colorectal Cancer Screening and Diagnostic Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Screening
        • 8.3.5.2.2. By Diagnostics
        • 8.3.5.2.3. By End User

9. Middle East & Africa Colorectal Cancer Screening and Diagnostic Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Screening
    • 9.2.2. By Diagnostics
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Colorectal Cancer Screening and Diagnostic Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Screening
        • 9.3.1.2.2. By Diagnostics
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Colorectal Cancer Screening and Diagnostic Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Screening
        • 9.3.2.2.2. By Diagnostics
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Colorectal Cancer Screening and Diagnostic Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Screening
        • 9.3.3.2.2. By Diagnostics
        • 9.3.3.2.3. By End User

10. South America Colorectal Cancer Screening and Diagnostic Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Screening
    • 10.2.2. By Diagnostics
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Colorectal Cancer Screening and Diagnostic Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Screening
        • 10.3.1.2.2. By Diagnostics
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Colorectal Cancer Screening and Diagnostic Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Screening
        • 10.3.2.2.2. By Diagnostics
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Colorectal Cancer Screening and Diagnostic Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Screening
        • 10.3.3.2.2. By Diagnostics
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Colorectal Cancer Screening and Diagnostic Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Exact Sciences Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories, Inc.
  • 15.3. F. Hoffmann-La Roche Ltd.
  • 15.4. Thermo Fisher Scientific Inc.
  • 15.5. Danaher Corporation
  • 15.6. Siemens Healthineers AG
  • 15.7. Hologic, Inc.
  • 15.8. Sysmex Corporation
  • 15.9. Bio-Rad Laboratories, Inc.
  • 15.10. Becton, Dickinson and Company

16. Strategic Recommendations

17. About Us & Disclaimer